Merck-Moderna Vaccine Helps Reduce Chances of Skin Cancer

A vaccine launched by Merck and Moderna was found to reduce the chances of skin cancer when used with the drug Keytruda, according to a new study released last week. The new results found that 79 percent of participants who received the vaccine and Keytruda stayed cancer-free for 18 months compared to just 62 percent of people who only received Merck’s Keytruda. The companies also said that the results of Phase Two showed mild side effects with the vaccine, like fatigue, injection site pain or chills. Read more from The Hill here.